Survival of Lung Cancer Patients by Histopathology in Taiwan from 2010 to 2016: A Nationwide Study

被引：5

作者：

Tsai, Hsuan-Chih ^{[1
,2
,3
]}

Huang, Jing-Yang ^{[4
,5
]}

Hsieh, Ming-Yu ^{[6
,7
]}

Wang, Bing-Yen ^{[7
,8
,9
,10
,11
]}

机构：

[1] Taichung Armed Forces Gen Hosp, Dept Family Med, Taichung 41148, Taiwan

[2] Taichung Vet Gen Hosp, Dept Occupat Med, Taichung 40705, Taiwan

[3] Natl Def Med Ctr, Sch Med, Taipei 11490, Taiwan

[4] Chung Shan Med Univ Hosp, Ctr Hlth Data Sci, Taichung 40201, Taiwan

[5] Chung Shan Med Univ, Inst Med, Taichung 40201, Taiwan

[6] Changhua Christian Hosp, Dept Otorhinolaryngol Head & Neck Surg, 135 Nanxium St, Changhua 50006, Taiwan

[7] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung 40227, Taiwan

[8] Changhua Christian Hosp, Dept Surg, Div Thorac Surg, Changhua 50006, Taiwan

[9] Chung Shan Med Univ, Sch Med, Taichung 40201, Taiwan

[10] Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung 80708, Taiwan

[11] Natl Chung Hsing Univ, Inst Genom & Bioinformat, Taichung 40227, Taiwan

来源：

JOURNAL OF CLINICAL MEDICINE | 2022年 / 11卷 / 19期

关键词：

histopathology; lung cancer; mortality; targeted therapies; POPULATION-BASED REGISTRIES; GLOBAL SURVEILLANCE; CELL CARCINOMA; IMPROVEMENT; RECEPTORS; EFFICACY; MUTATION; TRENDS;

D O I：

10.3390/jcm11195503

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: Lung cancer poses a tremendous threat to the modern world. According to Taiwan's Ministry of Health and Welfare, lung cancer took first place in total cancer deaths in 2021. This study investigated the overall lung cancer survival based on histopathology between 2010 and 2016 in Taiwan. Method: Data from 2010 to 2016 was collected from the Taiwan Cancer Registry (TCR). The characteristics and overall survival of 71,334 lung cancer patients were analyzed according to the tumor, node, metastasis (TNM) 7th staging system. Univariate and multivariate analyses were performed to identify differences in 1-year, 3-year, and 5-year survival between different histopathologies of lung cancer. Results: The 1-year overall survival rate increased from 54.07% in 2010 to 66.14% in 2016. The 3-year overall survival rate increased from 26.57% in 2010 to 41.12% in 2016 in all patients. Among the histopathologies of lung cancer, 3-year overall survival of adenocarcinoma patients increased the most and largely contributed to the increased 3-year overall survival of all lung cancer patients. Conclusions: The introduction of target therapy has led to a tremendous increase in overall survival for lung adenocarcinoma patients. However, target therapy differs by histopathology. Choosing the right target therapy and determining the correct histopathology of lung cancer is a pivotal key in increasing the overall survival of patients. Together with immune therapy, the landscape of lung cancer treatments is changing.

引用

页数：10